Abstract:727 Background: In order to identify targetable mutations, the Comprehensive Genomic Profiling (CGP) is an important tool. Technologies like extensive genomic NGS panels analyze multiple genes and biomarkers in a single assay. With multi-omics analysis, clinicians could increase the possibility to provide a tailored therapy. In literature, evidence about clinical applicability and performance of NGS are mainly derived from clinical trials and real-world experiences are lacking. Methods: On these bases, we performed a retrospective analysis of CGP data from a cohort comprising 1450 patients (pts) with a diagnosis of gastrointestinal tumor. The primary objective was to estimate adequacy and quality of CGP. As secondary objective, we identified mutations with an available but not already standard of care targeted treatment (TT), defined as gain, and we collected clinical data in those pts. The genomic analysis was performed using the FoundationOne CDx panel. Clinical impact of treated vs not-treated pts with TT was evaluated using 1:1 propensity score matching, according to tumor type, treatment line and gain gene mutation. Survival outcomes were estimated with Kaplan-Meier method and compared with Hazard Ratio (HR), univariate Cox regression. Results: In our population, 1310/1450 samples (90.3%) were adequate for NGS analysis. Failure rates were higher in biopsy samples compared to resections (p < 0.0001); the first cause was insufficient tumor DNA (p = 0.0020) especially for hepato-biliary-pancreatic neoplasms. Low-quality reports observed in 252/1310 (19.2%) were mainly due to inadequate DNA quality or extraction, regardless samples type. Gain molecular alterations were identified in 355/1450 pts (24.5%), corresponding to 28.1% of cases with informative reports and metastatic disease. Among them, based on the presence of gain alteration, 15.2% of pts received TT. Overall survival did not significantly differ in pts with and without gain mutations (HR 1.10, 95% CI: 0.93-1.30). An exploratory analysis of 17 matched treated vs untreated pts showed better overall survival (HR 0.26, 95% CI: 0.08-0.79) for the treated ones. More than 50% of pts with gain mutation did not received TT due to drug unavailability (lack of trials, expanded access programs or off-label use) or decreasing of general conditions (38.1%). Conclusions: The selection of appropriate samples and a bidirectional pathologist-clinician collaboration is crucial to enhance the feasibility of CGP. In our wide population, a relevant proportion of metastatic gastrointestinal pts presented a druggable gene alteration with a potential improvement of outcomes in case of availability of TT. Moreover, the time of testing is important to do not lose the right window of opportunity, especially in the metastatic setting.

Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma

A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma

Genetic Predisposition to Pheochromocytoma and Paraganglioma: 21 Years' Experience in the Field

Novel Gene Variants in a Nationwide Cohort of Patients with Pheochromocytoma and Paraganglioma

Hot Trends in Pheochromocytoma and Paraganglioma: Are We Getting Closer to Personalized Dynamic Prognostication?

Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures

Novel and recurrent genetic variants of VHL, SDHB, and RET genes in Chinese pheochromocytoma and paraganglioma patients

Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences

Personalized oncology in pheochromocytomas and paragangliomas: integrating genetic analysis with machine learning

The Molecular Classification of Pheochromocytomas and Paragangliomas: Discovering the Genomic and Immune Landscape of Metastatic Disease

Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.

Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma.

Cost-effectiveness of Genetic Testing of Endocrine Tumor Patients Using a Comprehensive Hereditary Cancer Gene Panel

Clinical and Genetic Features of Pediatric PCCs/PGLs Patients: a Single-Center Experience in China

Genetic landscape of Romanian PPGLs

Pheochromocytoma–Paraganglioma Syndrome: A Multiform Disease with Different Genotype and Phenotype Features

Personalized management for phaeochromocytomas and paragangliomas in Latin America: A genetic perspective

Overview of recent guidelines and consensus statements on initial screening and management of phaeochromocytoma and paraganglioma in SDHx pathogenic variant carriers and patients

Real-world performance and clinical outcome of comprehensive genomic profiling of gastrointestinal tumors: High-volume, single-center experience.

Metastatic Pheochromocytomas and Abdominal Paragangliomas

The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives